Lectin array and glycogene expression analyses of ovarian cancer cell line A2780 and its cisplatin-resistant derivate cell line A2780-cp

[1]  F. Guan,et al.  Identification of aberrantly expressed glycans in gastric cancer by integrated lectin microarray and mass spectrometric analyses , 2016, Oncotarget.

[2]  Yuanyuan Ruan,et al.  Integrated glycomic analysis of ovarian cancer side population cells , 2016, Clinical Proteomics.

[3]  L. Freire-de-Lima,et al.  Glycosylation in Cancer: Interplay between Multidrug Resistance and Epithelial-to-Mesenchymal Transition? , 2016, Front. Oncol..

[4]  A. Poveda,et al.  Advanced ovarian cancer: 20 years of ovarian cancer treatment. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  D. Gao,et al.  Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling , 2016, Cell Death and Disease.

[6]  Yee‐Shin Lin,et al.  Galectin-1-Induced Autophagy Facilitates Cisplatin Resistance of Hepatocellular Carcinoma , 2016, PloS one.

[7]  M. Nowicki,et al.  Inhibition of protein glycosylation reverses the MDR phenotype of cancer cell lines. , 2015, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[8]  Richard D Cummings,et al.  Protein glycosylation in cancer. , 2015, Annual review of pathology.

[9]  J. Sehouli,et al.  The Serum Glycome to Discriminate between Early-Stage Epithelial Ovarian Cancer and Benign Ovarian Diseases , 2014, Disease markers.

[10]  M. Anugraham,et al.  Specific Glycosylation of Membrane Proteins in Epithelial Ovarian Cancer Cell Lines: Glycan Structures Reflect Gene Expression and DNA Methylation Status * , 2014, Molecular & Cellular Proteomics.

[11]  Jodie L. Abrahams,et al.  Cell surface protein glycosylation in cancer , 2014, Proteomics.

[12]  Xiaobo Song,et al.  Reversal Effect of ST6GAL 1 on Multidrug Resistance in Human Leukemia by Regulating the PI3K/Akt Pathway and the Expression of P-gp and MRP1 , 2014, PloS one.

[13]  H. Zhou,et al.  FUT family mediates the multidrug resistance of human hepatocellular carcinoma via the PI3K/Akt signaling pathway , 2013, Cell Death and Disease.

[14]  W. Alley,et al.  Comparative profiling of N-glycans isolated from serum samples of ovarian cancer patients and analyzed by microchip electrophoresis. , 2013, Journal of proteome research.

[15]  Jianxin Gu,et al.  N-acetylglucosaminyltransferase V confers hepatoma cells with resistance to anoikis through EGFR/PAK1 activation. , 2013, Glycobiology.

[16]  J. Sehouli,et al.  Serum glycome profiling: a biomarker for diagnosis of ovarian cancer. , 2013, Journal of proteome research.

[17]  C. Landen,et al.  ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells , 2013, Journal of Ovarian Research.

[18]  W. Alley,et al.  N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients. , 2012, Journal of proteome research.

[19]  B. Kong,et al.  Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis , 2012, Journal of Hematology & Oncology.

[20]  V. Hogan,et al.  Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment , 2010, Cell Death and Disease.

[21]  E. Lengyel.  Ovarian cancer development and metastasis. , 2010, The American journal of pathology.

[22]  C. Sessa,et al.  Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  Y. Assaraf,et al.  Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin. , 2010, Biochemical pharmacology.

[24]  Z. Siddik,et al.  Cisplatin: mode of cytotoxic action and molecular basis of resistance , 2003, Oncogene.

[25]  E. Partridge,et al.  Epithelial ovarian cancer: Prevention, diagnosis, and treatment , 1999, CA: a cancer journal for clinicians.

[26]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[27]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.